Trial Profile

Phase II trial of ATI 9242 in patients with schizophrenia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 05 May 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATI 9242 (Primary)
Indications Schizophrenia
Focus Therapeutic Use
Sponsors Braeburn Pharmaceuticals

Most Recent Events

05 May 2015 New trial record
01 May 2015 Braeburn Pharmaceuticals has licensed development and commercialisation rights to ATI-9242 from Oncothyreon and is planning to develop a long-acting formulation and to initiate a phase II trial in 2015, according to a media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com